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ABSTRACT The Epstein-Barr virus (EBV) immediate
early gene product BZLF1 was localized by indirect immuno-
fluorescence to the cytoplasm of the basal epithelial layer at the
lateral border and dorsum of tongue in human immunodefi-
ciency virus-infected and -seronegative patients. Two biopsies
of oral hairy leukoplakia revealed a sporadic cytoplasmic
staining of the BHRF1 and BRLF1 gene products in the basal
epithelial layer. The widespread presence ofBZLF1 in the basal
epithelial layer indicated that this cell layer contained EBV
DNA and was probably directly infected by EBV. Nuclear
localization of the immediate early and early gene products
BZLF1, BHRF1, BRLF1, and BMLF1 was limited to oral hairy
leukoplakia in human immunodeficiency virus-seropositive
patients and revealed a codistribution with the virus capsid
antigen. Our results indicate that the epithelium of the tongue
is a potential reservoir for EBV and that in heavily immuno-
compromised patients EBV may move from the cytoplasm to
the nucleus with increasing differentiation and be coactivated
there during the terminal differentiation ofepithelial cells at the
lateral border and dorsum of tongue.
Epstein-Barr virus (EBV) is a ubiquitous herpesvirus with a
linear double-stranded DNA genome, which has been com-
pletely sequenced (1, 2). It causes polyclonal immortalization
ofhuman B cells both in vivo and in vitro (for review, see ref.
3) and persists within latently infected cells as multiple,
covalently closed circular episomes (4). EBV infection of
lymphoid cells is primarily latent as indicated by the absence
ofantibodies to early EBV-encoded antigens, such as p54 and
p138 in healthy EBV-seropositive individuals (5). In latently
infected cells viral gene expression is restricted to a few viral
products: the EBV nuclear antigens (for review, see ref. 6),
the BNLF1 membrane protein (latent membrane protein; ref.
7), EBV-encoded small RNAs (8), and terminal protein (9).
The cellular and viral factors that determine whether EBV
infection is latent or productive are mainly unknown and
depend on the host cell (10).
The concept of strict B-lymphocyte tropism has been
central to discussion of the biology ofEBV since the discov-
ery of this herpesvirus. The observation that epithelial cells
in nasopharyngeal carcinoma are latently infected with EBV
and that lytic expression ofEBV occurs in epithelial cells of
the parotid gland (11) and other sites of the human body (12)
clearly points to a complex biology of this herpesvirus.
Virus binding to B cells occurs via a specific interaction
between the major envelope glycoprotein gp340 and the C3d
receptor molecule (CD21; refs. 13 and 14) and it seems that
the specificity of gp340-CD21 binding plays a major role in
determining the viral B lymphotropism (15).
The presence of EBV in the upper two-thirds of the
epithelium in oral hairy leukoplakia (OHL) was originally
described by Greenspan et al. (16) and was later confirmed by
ultrastructural studies (17), immunohistochemistry, and in
situ hybridization (18-20).
The means by which EBV gains access to epithelial cells in
general and the questions of which epithelial cell layer in
OHL could be infected by EBV and ofhow the virus reaches
the replicating cells in OHL have been the subject of numer-
ous studies (15, 21-24). Different modes of infection have
been suggested: Receptor molecules similar but not identical
to CD21 have been reported from undifferentiated epithelial
cells of the oropharynx (22, 25). It is possible that basal
epithelial cells in OHL could be infected through such
receptors or via cell fusion (21) by EBV-infected B lympho-
cytes from peripheral blood. Production of EBV in OHL
could be initiated later as a consequence of cellular differ-
entiation (26). It has been shown that human epithelial cells
of normal nasopharynx and tonsil (15), as well as of the upper
and middle spinous cell layer ofOHL (23), express a 200-kDa
surface molecule that is antigenetically related to, but not
identical with, the CD21 antigen of B cells (15). It is possible
that this cell layer, where lytic expression ofEBV is observed
in OHL, could be infected by free virus in the saliva from the
parotid gland. But this receptor molecule, which is detected
by monoclonal antibody HB5, is not limited to the lateral
border of tongue and is also present in other parakeratinized
areas-i.e., gingiva, soft palate (23)-where lytic expression
of EBV has so far not been observed.
To get further insight into the mode and time of infection
of epithelial cells we used antibodies to regulatory and
structural gene products of EBV on biopsy material of
HIV-seronegative and HIV-infected patients.
METHODS
Biopsies. Thirty-three biopsies (Table 1) were taken under
local anesthesia for diagnostic reasons or during surgery for
other reasons. Biopsies of uninvolved mucosa were taken in
a systematic manner from volunteers after information about
the proposed study. Immediately after removal biopsies were
divided. One portion was fixed with 10%o formalin and
embedded in paraffin for routine histology (hematoxylin/
eosin and periodic acid/Schiff staining). The other portion
was frozen in liquid nitrogen and stored at -750C.
Abbreviations: EBV, Epstein-Barr virus; OHL, oral hairy leuko-
plakia; HIV, human immunodeficiency virus; VCA, viral capsid
antigen; ORF, open reading frame.
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Table 1. Clinical data of biopsies examined
Histological diagnosis Localization n Sex/age, yr HIV status CDC stage
Hairy leukoplakia Lateral border of tongue 12 M/30 (23-59) + CIV
Normal oral mucosa Lateral border of tongue 3 M/41 (34-52) + CIII
Normal oral mucosa Orthokeratinized gingiva 5 M/32 (24-37) + CIV
Smokers' leukoplakia Lateral border of tongue 4 M/42 (30-57) -
Normal oral mucosa Tongue 6 M/32 (5-53) -
Normal oral mucosa Tongue 1 F/40
Squamous cell carcinoma Tongue 1 M/72
Fibroma Orthokeratinized gingiva 1 M/67
n, No. individuals; M, male; F, female; ages are given as mean and range; CDC, Centers for Disease Control.
All patients were examined for human immunodeficiency
virus (HIV) infection by ELISA and Western blotting. The
clinical status was diagnosed according to the Centers for
Disease Control definition (27). All patients were examined
for EBV infection and demonstrated IgG and IgM anti-viral
capsid antigen (VCA) antibodies except the youngest, a
5-year-old patient, who did not show anti-EBV IgG and IgM
antibodies.
For indirect immunofluorescence, cryostat sections (5 ,um)
were air dried at room temperature for 2 h and fixed with
chloroform/acetone for 5 min at 5°C. Sections were incu-
bated first with primary antibody (dilution, 1:20) and then
with tetramethyl-rhodamine isothiocyanate (TRITC)-
conjugated goat anti-rabbit or fluorescein isothiocyanate
(FITC)-conjugated goat anti-mouse second antibody (dilu-
tion, 1:20; Jackson ImmunoResearch). After each step sec-
tions were washed three times with phosphate-buffered sa-
line, pH 7.2. The localization of BZLF1 and BcLF1 (p150)
included double-staining experiments. These sections were
incubated first with antiserum to BZLF1 followed by the
TRITC-conjugated second antibody and then with monoclo-
nal antibody to BcLF1 followed by the FITC-conjugated goat
anti-mouse IgG (dilution, 1:20; Jackson ImmunoResearch).
Controls using second antibodies only were included for
every biopsy. Immunostaining was visualized with a Leitz
Orthoplan microscope and photographed on Ilford HP5 films.
Antibodies. A monoclonal antibody specific for open read-
ing frame (ORF) BcLF1 was produced against authentic viral
protein by inoculation of EBV-VCA positive P3HR-1 cells
(W.J., Helga Mairhofer, and H.W., unpublished results) and
was demonstrated to be highly specific on semithin cryostat
sections ofOHL (17). Sera against the proteins expressed by
ORFs BZLF1 (amino acids 90-166 of the ORF; exon 1),
FIG. 1. Normal oral mucosa of the dorsum of the tongue of a
HIV-seronegative patient. Strong cytoplasmic fluorescence for
BZLF1 is shown in the basal epithelial layer. (x600.)
BMLF1 (amino acids 1-165), BRLF1 (amino acids 400-600),
BHRF1 (amino acids 24-138) have been derived using ,8-ga-
lactosidase fusion proteins as described (28, 29). A second
polyclonal antiserum specific for amino acids 175-189 of
BZLF1 (exon 2) was raised by inoculation of synthetic
peptides in rabbits. A c-fos antiserum was kindly provided by
R. Muller (Marburg, F.R.G.).
RESULTS
Biopsies from HIV-Seronegative Patients. All biopsies were
completely negative for BRLF1, BMLF1, and BcLF1 (p150)
and for the antiserum against c-fos. Four biopsies from
normal tongue (three males and one female) and two from
smokers' leukoplakia revealed an intense cytoplasmatic flu-
orescence for BZLF1 in the basal epithelial layer (Fig. 1). The
presence of BZLF1 in three of these biopsies from normal
tongue was not limited to the lateral border oftongue (Fig. 2).
The fluorescence for BZLF1 was not present in all basal
epithelial cells, extensive areas were negative (Fig. 3). Two
biopsies from smokers' leukoplakia and three biopsies from
normal tongue, including multiple sections from an EBV-
seronegative five-year-old patient, did not show any fluores-
cence for BZLF1 in the basal epithelial layer at the lateral
border of tongue. The antibodies against exons 1 and 2 of
BZLF1 revealed similar results.
Biopsies from HlIV-Infected Patients. Immunolabeling for
antibodies against the ORFs BcLF1 (VCA), BRLF1,
BMLF1, and BHRF1 was limited to OHL biopsies (Fig. 3).
The antiserum against c-fos did not show any immunoreac-
tion as was also noted in HIV-seronegative patients.
BcLFJ (p50). The VCA was observed only in the nuclei of
epithelial cells and in the extracellular space in the upper
stratum spinosum (Fig. 4A).
$ ~~~~~BZLF,
FIG. 2. Schematic drawing of the dorsum and lateral border of
tongue. Areas that were found to be positive for BZLF1 in the
cytoplasm of the basal epithelial layer in our biopsy material are
indicated.
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FIG. 3. In HIV-seronegative patients, BZLF1 was localized to the cytoplasm of the basal epithelial layer at the lateral border or dorsum of
tongue, with the immunolabeling showing as a patchlike distribution and extensive areas between labeled cells remaining unstained. In OHL
patients, BZLF1 fluorescence was observed in the cytoplasm of nearly the entire basal epithelial layer. Nuclear staining for immediate early
and early antigens as well as virus structural proteins (BcLF1, VCA) indicates the limitation of the lytic cycle of EBV to the upper stratum
spinosum and the overlying ballooned keratinocytes. All proteins examined revealed a nuclear codistribution in this location.
BZLFL. All OHL biopsies showed an intense fluorescence
for BZLF1 throughout almost the entire basal epithelial layer
(Fig. 4B). The adjacent stratum spinosum was completely
negative. In the upper stratum spinosum and in the ballooned
keratinocytes a nuclear fluorescence was noted, and double
immunofluorescence experiments revealed in this area a
nuclear codistribution of BZLF1 and BcLF1 (Fig. 4).
Only one biopsy from normal lateral tongue (Centers for
Disease Control stage CIII) showed intense intracytoplas-
matic fluorescence in the basal epithelial layer. The other two
biopsies from lateral tongue were negative as was the or-
thokeratinized gingiva. The antibodies against the exons 1
and 2 gave similar results.
BRLFL. OHL biopsies showed a nuclear fluorescence for
BRLF1 in the upper stratum spinosum and in the overlying
ballooned keratinocytes (Fig. 3). Two patients revealed a
sporadic but strong cytoplasmatic fluorescence in epithelial
cells of the basal epithelial layer.
BMLFL. BMLF1 fluorescence was observed only in the
upper stratum spinosum of OHL biopsies and showed a
nuclear codistribution with BcLF1 fluorescence (Figs. 3 and
5).
BHRFL. BHRF1 showed as a nuclear fluorescence in the
upper stratum spinosum and in the overlying ballooned
keratinocytes of OHL biopsies as was observed for BcLF1
(Fig. 3). In two patients a further cytoplasmic staining was
noted in the basal epithelial layer.
DISCUSSION
In vitro models have shown that latent EBV infection is
controlled by complex interactions between B and T cells as
well as their secreted products, immunoglobulins, interfer-
ons, and interleukins. An important component of the inhi-
bition of lytic expression in vivo seems to be cooperation of
HLA-restricted cytotoxic T cells and the CD4' subset (30,
31). This EBV-directed immune elimination does not reach
all sites of the human body and it has been shown that cells
of the ductal epithelium of the parotid gland can undergo a
complete lytic cycle in nonimmunocompromised patients
(11).
The replication of EBV in epithelial cells of the stratum
spinosum at the lateral border of tongue in immunocompro-
mised patients is an obvious sign that the immune system has
lost the ability to eliminate cells expressing other than latent
gene products ofEBV. Recent individual reports have shown
that the lytic cycle ofEBV replication in OHL is not limited
to immunocompromised patients under HIV infection (32).
OHL is therefore not a specific sign ofHIV infection, but is
related to immunosuppression in general (33).
We have shown the presence in HIV-seropositive patients
of the EBV immediate early gene product BZLF1 and
occasionally of BHRF1 and BRLF1 in the cytoplasm of the
basal epithelial layer of the tongue. These findings indicate
that this cell layer contains EBV genomes and is probably
directly infected by EBV. In particular the demonstration of
BZLF1 in immunocompromised HIV-infected as well as
HIV-seronegative patients indicates further that the tongue is
a potential reservoir for EBV.
The patchlike distribution of BZLF1-specific cytoplasmic
fluorescence in the basal epithelial layer in HIV-seronegative
patients suggests that this epithelial layer is probably not
continuously infected. The presence ofEBV in basal epithe-
lial cells could result from a horizontal transmission of viral
genomes during the proliferation of epithelial progenitor
cells.
The increase of BZLF1-positive cells in the basal epithelial
layer ofOHL may be a consequence of the general loss ofthe
immune system to eliminate cells expressing other than latent
Proc. Natl. Acad. Sci. USA 88 (1991)
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FIG. 4. OHL biopsies. (A) BcLF1.(VCA). Strong fluorescence is shown in the nuclei of epithelial cells and in the extracellular space in the
upper stratum spinosum. (B) BZLF1. Strong cytoplasmic fluorescence is shown in the basal epithelial layer and weaker nuclear staining is shown
in the upper stratum spinosum. (x600.)
gene products as indicated by the lytic cycle ofEBV expres-
sion in the stratum spinosum. When this is interpreted as a
defect in the elimination of cells entering a lytic cycle of viral
replication one can also assume that further epithelial cells
could be infected through EBV-expressing B lymphocytes
from peripheral blood.
We have shown that the presence of the EBV immediate
early gene product BZLF1 in the cytoplasm ofbasal epithelial
cells is not limited to the lateral border of the tongue. Recent
FIG. 5. In OHL biopsies BMLF1 fluorescence was limited to the
nuclei of epithelial cells in the stratum spinosum. It was first
observed at the periphery ofthe nuclei in the lower stratum spinosum
(arrow). (x750.)
clinical findings underline these results with the description
of lytic expression of EBV at the dorsum of tongue (34, 35).
To exclude cross-reactivity between BZLF1 and c-fos in
basal epithelial cells (36) we used antibodies against dihferent
exons ofBZLF1 and an antibody to c-fos. Our results exclude
a cross-reactivity with c-fos in our biopsy material. A further
hint for the specificity of the immunohistochemical detection
ofBZLF1 in the basal layer was the detection ofBHRF1 and
BRLF1 in this location. The fact that BHRF1 was observed
in two samples is in agreement with observations by Austin
et al. (37) of transient expression of this protein in lympho-
cytes. However, our observation does not necessarily sup-
port direct involvement of this gene in induction of the lytic
cycle. The sporadic observation of BRLF1 may reflect a
tissue-specific regulatory event and low levels of expression.
In the stratum spinosum, where BZLF1 was detected in the
nuclei, late viral genes are expressed in regions positive for
BZLF1. It has been shown that expression of BZLF1 is
sufficient to disrupt latency (38, 39). Our findings strongly
suggest that a nuclear localization for BZLF1 (29) is neces-
sary for its trans-activating function on other EBV genes
(39-42). BZLF1 may move from cytoplasm to nucleus with
increasing differentiation in immunocompromised patients
and the mechanism may be similar to that ofnuclear factor KB
in HIV-infected T cells (43), which is present in an inactive
form due to formation of a complex with a cellular protein in
nonactivated cells and changes its location in response to
external stimuli. Alternatively, a cellular protein may be
required for activation ofBZLF1, such as the cellular protein
E2F, which activates the adenovirus-encoded EMA protein in
adenovirus-infected cells (44).
Various studies employing in situ hybridization have failed
to detect low copy numbers of EBV-specific nucleic acids in
the basal epithelial layer of OHL because of the limited
sensitivity of this technique (18, 45). Independent proof of
EBV infection of the basal layer, in addition to the demon-
Medical Sciences: Becker et al.
8336 Medical Sciences: Becker et al.
stration of BZLF1, is desirable. But there art technical
constraints at this time to block otherwise widely used
technical approaches. The polymerase chain reaction, which
is a highly sensitive technique to detect EBV in HIV-infected
patients (45), can in our opinion not be applied for this
question, because of the difficulties to extract only the basal
layer of the stratified epithelium and to exclude contamina-
tion with free virus shedding from oropharyngeal mucosa.
In conclusion, our findings show that the basal epithelial
cell layer of the lateral border and the dorsum of tongue is
probably a potential reservoir for EBV in HIV-seropositive
and in nonimmunocompromised HIV-seronegative individ-
uals. In heavily immunosuppressed patients latently EBV-
infected epithelial cells may be coactivated during terminal
differentiation of the epithelium. Due to the regular stratifi-
cation of the epithelium OHL is an excellent model to study
the host cell-dependent activation of EBV genes using anti-
bodies to different gene products until more-sensitive tech-
niques for in situ hybridization are available.
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